Targeting the PI3K/AKT/GSK-3β signaling pathway presents multiple therapeutic mechanisms for combating liver cancer, including inhibition of key pathway components, combination therapies, targeting glycolysis and metabolic pathways, modulating the tumor microenvironment, and regulating gene expression through non-coding RNAs. Here, AKT1 is linked to neoplasm.